Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy.
about
Host nucleotide polymorphism in hepatitis B virus-associated hepatocellular carcinomaOutcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factorsHepatitis B infection is associated with an increased incidence of thrombocytopenia in healthy adults without cirrhosis.Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates.Transient elastography in chronic hepatitis B: an Asian perspective.Mathematical models of e-antigen mediated immune tolerance and activation following prenatal HBV infection.Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbationQuantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.Effect of lamivudine in HBeAg-positive chronic hepatitis B: discordant effect on HBeAg and HBV DNA according to pretreatment ALT levelChronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxisHBsAg, HBeAg and HBV DNA level changes and precore/basal core promoter mutations in the natural history of chronic hepatitis B in Indonesian patients.How many valid measurements are necessary to assess liver fibrosis using FibroScan® in patients with chronic viral hepatitis? An analysis of subjects with at least 10 valid measurements.Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric AssayAntiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study.Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver.Serolological Profile Among HBsAg-Positive Infections in Southeast China: A Community-Based Study.Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion.Expression of MicroRNA-155 is Downregulated in Peripheral Blood Mononuclear Cells of Chronic Hepatitis B Patients.Association of early age at establishment of chronic hepatitis B infection with persistent viral replication, liver cirrhosis and hepatocellular carcinoma: a systematic reviewScientific publications in gastroenterology and hepatology journals from Chinese authors in various parts of North Asia: 10-year survey of literature.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.UGT2B28 genomic variation is associated with hepatitis B e-antigen seroconversion in response to antiviral therapy.Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases.Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study.HBsAg levels in HBeAg-positive chronic hepatitis B patients with different immune conditions.Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients.Therapeutic vaccines in HBV: lessons from HCV.Hepatitis B virus infection in children.Immune reconstitution inflammatory syndrome in HIV infection: taking the bad with the good.Co-infection assessment in HBV, HCV, and HIV patients in Western Saudi Arabia.Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study.Low serum albumin and advanced age predict early mortality in Asian patients with extreme elevations of serum aminotransferase.Hepatitis B virus and host factors.Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study.Cure for immune-tolerant hepatitis B in children: is it an achievable target with sequential combo therapy with lamivudine and interferon?Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice.Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
P2860
Q26750792-38049FFA-54B0-459D-8B17-8FB72B00E7FCQ27020938-79925452-AAB2-4A62-AAFC-859E3DE3EA0EQ33436901-92C6CD98-87AB-47B2-A549-403C37375B87Q34168465-3B077174-B2A3-4322-9192-7E8574A7BF22Q34284732-EEF908DF-8BCA-4021-8C3E-F00F5C23DAE1Q34328969-99D26B20-8488-41E8-B857-425C058246D1Q34553545-BEBC27B5-9DFE-48DB-A627-48E4B75CD683Q34674838-4A417C9D-ADF0-4805-95A6-5FB9E75923E4Q35045329-E819D3E6-289D-4E45-940A-EAFD8392200FQ35596827-C0F27A6A-9A2E-42F8-A15D-2E0C5592D85FQ35706571-D38455E1-2C8A-4DDD-9C7B-29947897A685Q35767497-15D00097-B639-4913-8A45-942C0FB5C3B5Q36037164-BBB7E648-7DD0-4D45-839E-A8D969E45DE6Q36094811-FD9C55E5-5364-4FD1-BDAF-2E4CED2E2467Q36135493-CD6E6D43-0C26-4A2D-9C92-1B73AFD3E6EFQ36151658-5061CFA7-AFCA-466F-B4E0-56D4793C73DCQ36577653-16E10F71-8B06-4582-AC98-F2F9B752D69BQ36661213-BB1F0904-E0C3-4390-8172-408CB85074A8Q36738157-C3267F0D-7A45-418B-991A-B6A098D50780Q36806000-FC7187FA-E2F6-47AA-82D3-1B5784CF58D7Q37027805-8C6FC7FE-BCDB-458C-A66C-ED2F2B009ADFQ37101694-8C0BA2B8-EEF7-4B8A-BB86-7BC5350E7F24Q37278241-576B28E3-B7CE-4DC0-8CC8-8345A9AA3109Q37282393-3356E070-ADE4-4A61-8F05-4C7871C7A00AQ37386578-96681B13-80C3-43ED-B19B-954846CF6EBCQ37444284-EE8D2955-0963-4F80-869F-83344960125AQ37708054-FA486792-A7F6-4FC6-B377-D92C90B851E5Q38086312-6F312601-2239-4F7F-B000-F36E2BE7E45CQ38312255-CD48F4B9-A5DF-4434-9275-2670E4063B75Q38365905-2E46F2D6-D8D8-441C-AFD9-83A05AF185E1Q38995954-D8ADEFEC-66E9-40D7-868A-39CB8E21CD89Q39983596-029B8768-E76D-4CA5-B957-62EF9639264DQ40390552-57060B51-0057-4A69-8813-59F286656493Q40908595-92CCBB42-93CC-40BB-9A7C-E34A640548FAQ41955691-7E9BCA41-00C2-4862-AC4D-FE7CECE08C06Q41968114-58F1FEC1-A3E2-43BC-BF98-EF35199568F9Q43466658-55B0C663-746B-4341-A807-D50A0BDB87A5Q45002798-560CB52E-BC9F-4FDE-85DA-75B8FC0C03BAQ45105367-9C537E1C-9C06-4377-BBB7-E9B6CDBD8BBFQ45369749-6B0FA637-3204-4757-9556-CB695D9B2DDA
P2860
Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Hepatitis flares and hepatitis ...... nti-hepatitis B virus therapy.
@ast
Hepatitis flares and hepatitis ...... nti-hepatitis B virus therapy.
@en
type
label
Hepatitis flares and hepatitis ...... nti-hepatitis B virus therapy.
@ast
Hepatitis flares and hepatitis ...... nti-hepatitis B virus therapy.
@en
prefLabel
Hepatitis flares and hepatitis ...... nti-hepatitis B virus therapy.
@ast
Hepatitis flares and hepatitis ...... nti-hepatitis B virus therapy.
@en
P2860
P1476
Hepatitis flares and hepatitis ...... nti-hepatitis B virus therapy.
@en
P2860
P304
P356
10.1046/J.1440-1746.2003.02976.X
P50
P577
2003-03-01T00:00:00Z